Abstract Objective Prevalence of Lewy body dementias (LBD) is second only to Alzheimer's
disease (AD) among people with neurodegenerative dementia. LBD cause earlier mortality …

Objectives: Lewy body dementia (LBD) is the second most prevalent neurodegenerative
dementia and it causes more morbidity and mortality than Alzheimer's disease. Several …

Abstract Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative
disorder in the elderly. The development and progression of DLB remain unclear. In this …

Objective There is an urgent clinical need for identifying blood-based diagnostic biomarkers
for Dementia with Lewy Bodies (DLB). Transcriptomic studies have reported unique RNA …

Background The current genome-wide association study (GWAS) of Lewy body dementia
(LBD) suffers from low power due to a limited sample size. In addition, the genetic …

Abstract Parkinson's disease (PD), Parkinson's disease with dementia (PDD) and dementia
with Lewy bodies (DLB) are three clinically, genetically and neuropathologically overlapping …

Background Based on amyloid cascade and tau hypotheses, protein biomarkers of different
Aβ and tau species in cerebrospinal fluid (CSF) and blood/plasma/serum have been …

Objectives Lewy body dementia (LBD) causes more morbidity, disability, and earlier
mortality than Alzheimer disease. Molecular mechanisms underlying neurodegeneration in …

Neurodegenerative disorders such as Alzheimer's disease (AD), Lewy body diseases (LBD),
and the amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) spectrum are …

Abstract Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative
dementia. Despite considerable research progress, there remain gaps in our understanding …